Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079071279> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2079071279 endingPage "85" @default.
- W2079071279 startingPage "79" @default.
- W2079071279 abstract "Objectives: The present study investigated the early efficacy of naftopidil against lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Methods: Subjects comprised patients with LUTS suggestive of BPH who were followed prospectively for 8 weeks. Inclusion criteria were: (i) international prostate symptom score (IPSS) ≥8; (ii) no previous treatment for BPH; and (iii) eligibility for naftopidil monotherapy. IPSS and quality of life index were evaluated, and uroflowmetry and residual urine volume were determined optionally. In the previous study, patients who demonstrated a decrease in total American Urological Association symptom score of 25% or more from baseline were considered responders. The ratio of onset of efficacy of naftopidil was calculated by the ratio of the number of responder in each group with the starting dose. Results: Naftopidil efficacy was analyzed for 243 patients. Significant improvement of IPSS was achieved within 1–3 days after medication. Starting dosage and average dosage were identified as factors associated with the period until onset of naftopidil efficacy. Onset of efficacy was significantly quicker with a starting dosage of 50 mg/day as compared with 25 mg/day (P = 0.0047). However, ratios of onset of efficacy with starting dosages of 25, 50 and 75 mg/day were 77.9, 76.7 and 85.7%, respectively, showing no significant difference between groups (P = 0.7463). Duration to onset of efficacy with naftopidil dosage ≥50 mg/day was 11.2 days, significantly early compared to dosage <50 mg/day. Incidence of adverse effect was 3.8%. Conclusion: Naftopidil showed early effects against LUTS suggestive of BPH within a few days." @default.
- W2079071279 created "2016-06-24" @default.
- W2079071279 creator A5049100460 @default.
- W2079071279 creator A5049257162 @default.
- W2079071279 creator A5071020559 @default.
- W2079071279 creator A5084498556 @default.
- W2079071279 creator A5091264322 @default.
- W2079071279 date "2010-12-01" @default.
- W2079071279 modified "2023-09-25" @default.
- W2079071279 title "Early Efficacy of an α1 Adrenoceptor Antagonist, Naftopidil, against Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia" @default.
- W2079071279 cites W1575890696 @default.
- W2079071279 cites W1586377469 @default.
- W2079071279 cites W1917454581 @default.
- W2079071279 cites W1964254548 @default.
- W2079071279 cites W1966345715 @default.
- W2079071279 cites W1991315347 @default.
- W2079071279 cites W2020664021 @default.
- W2079071279 cites W2094929908 @default.
- W2079071279 cites W2151855495 @default.
- W2079071279 cites W4211144482 @default.
- W2079071279 cites W4236163484 @default.
- W2079071279 doi "https://doi.org/10.1111/j.1757-5672.2010.00084.x" @default.
- W2079071279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26676391" @default.
- W2079071279 hasPublicationYear "2010" @default.
- W2079071279 type Work @default.
- W2079071279 sameAs 2079071279 @default.
- W2079071279 citedByCount "1" @default.
- W2079071279 countsByYear W20790712792020 @default.
- W2079071279 crossrefType "journal-article" @default.
- W2079071279 hasAuthorship W2079071279A5049100460 @default.
- W2079071279 hasAuthorship W2079071279A5049257162 @default.
- W2079071279 hasAuthorship W2079071279A5071020559 @default.
- W2079071279 hasAuthorship W2079071279A5084498556 @default.
- W2079071279 hasAuthorship W2079071279A5091264322 @default.
- W2079071279 hasConcept C121608353 @default.
- W2079071279 hasConcept C126322002 @default.
- W2079071279 hasConcept C126894567 @default.
- W2079071279 hasConcept C162156334 @default.
- W2079071279 hasConcept C197934379 @default.
- W2079071279 hasConcept C2776235491 @default.
- W2079071279 hasConcept C2776547966 @default.
- W2079071279 hasConcept C2777562237 @default.
- W2079071279 hasConcept C2779478474 @default.
- W2079071279 hasConcept C71924100 @default.
- W2079071279 hasConcept C77411442 @default.
- W2079071279 hasConceptScore W2079071279C121608353 @default.
- W2079071279 hasConceptScore W2079071279C126322002 @default.
- W2079071279 hasConceptScore W2079071279C126894567 @default.
- W2079071279 hasConceptScore W2079071279C162156334 @default.
- W2079071279 hasConceptScore W2079071279C197934379 @default.
- W2079071279 hasConceptScore W2079071279C2776235491 @default.
- W2079071279 hasConceptScore W2079071279C2776547966 @default.
- W2079071279 hasConceptScore W2079071279C2777562237 @default.
- W2079071279 hasConceptScore W2079071279C2779478474 @default.
- W2079071279 hasConceptScore W2079071279C71924100 @default.
- W2079071279 hasConceptScore W2079071279C77411442 @default.
- W2079071279 hasIssue "2" @default.
- W2079071279 hasLocation W20790712791 @default.
- W2079071279 hasLocation W20790712792 @default.
- W2079071279 hasOpenAccess W2079071279 @default.
- W2079071279 hasPrimaryLocation W20790712791 @default.
- W2079071279 hasRelatedWork W1580872362 @default.
- W2079071279 hasRelatedWork W1978630268 @default.
- W2079071279 hasRelatedWork W2013357874 @default.
- W2079071279 hasRelatedWork W2116616598 @default.
- W2079071279 hasRelatedWork W2142133236 @default.
- W2079071279 hasRelatedWork W2330542927 @default.
- W2079071279 hasRelatedWork W2414475439 @default.
- W2079071279 hasRelatedWork W3006945038 @default.
- W2079071279 hasRelatedWork W3032232204 @default.
- W2079071279 hasRelatedWork W3175503089 @default.
- W2079071279 hasVolume "3" @default.
- W2079071279 isParatext "false" @default.
- W2079071279 isRetracted "false" @default.
- W2079071279 magId "2079071279" @default.
- W2079071279 workType "article" @default.